FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer

Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more

FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology as a Toxicology Testing Platform for Understanding How Products Affect Human Health and Safety

April 11, 2017 Cooperative Research and Development Agreement (CRADA) to advance and qualify ‘Human Emulation System’ to meet regulatory evaluation criteria for product testing BOSTON, Mass., April 11, 2017 — Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration’s (FDA) Office... Read more

New Analysis Kit Enables Efficient Measurement of 1 mm or Smaller Contaminants with Energy Dispersive X-Ray Fluorescence Spectrometers

Contaminant analysis has become increasingly important for manufacturing and quality control departments in a wide variety of industries, such as foods, electrical/electronics, and raw materials. In the field of contaminant analysis, EDX spectrometers are mainly used to analyze metals, due to their performance for analyzing inorganic elements. Shimadzu EDX spectrometers are used in a wide... Read more

VWR Signs European Distribution Agreement for J.T.Baker® and Macron Fine Chemicals™ Laboratory Pharmaceutical and Production Chemistries

Radnor, PA – March 9, 2017 – VWR (NASDAQ: VWR), the leading global independent provider of products and service solutions to laboratory and production customers, is excited to announce an agreement with Avantor® Performance Materials, LLC. This agreement will allow VWR to distribute Avantor’s beaker-to-bulk portfolio of J.T.Baker® and Macron Fine Chemicals™ brand laboratory and... Read more

908 Devices’ Commercialization of Oak Ridge National Laboratory Technology Honored with Federal Laboratory Consortium Award

03.06.17 Life Sciences, Applied Markets, Safety & Security 908 Devices, a pioneer of analytical devices for chemical and biomolecule analysis, today announced that its efforts to develop, build and launch commercial products based on technology licensed from Oak Ridge National Laboratory (ORNL) have been honored by the Federal Laboratory Consortium for Technology Transfer as an... Read more